1、THE PERIOPERATIVEPIVOTNAVIGATING THE NEW FRONTIER FOR IMMUNOTHERAPY IN EARLY-STAGE CANCERSJoel Sandler,PhDEric Blouin,BHSc Ipsos|2025|all rights reservedTHE PERIOPERATIVE PIVOT:NAVIGATING THE NEW MEDICAL AND COMMERCIAL FRONTIER IN EARLY-STAGE CANCERExecutive summary2For the past decade,immune checkp

2、oint inhibitors(PD-1/PD-L1 mAbs)have revolutionized the management of advanced cancer patients,converting end-stage settings into what can now be rightly considered treatable and in some cases,curable cancers.Now,the frontier is moving to an earlier,more complex battleground:the perioperative(neoadj

3、uvant and adjuvant)setting for resectablesolid tumors.This perioperative pivot represents a multi-billion-dollar opportunity,but it is also a“strategic black box”fraught with unique medical,regulatory,competitive,and commercial challenges.Success in this new landscape requires moving beyond traditio

4、nal market research to an integrated,strategic approach that can decipher new stakeholder dynamics,navigate complex endpoints,and shape physician behavior in a curative-intent setting.Ipsos|2025|all rights reservedTHE PERIOPERATIVE PIVOT:NAVIGATING THE NEW MEDICAL AND COMMERCIAL FRONTIER IN EARLY-ST

5、AGE CANCERAt a glanceThe PD-1/PD-L1 frontier has moved to earlier-stage cancers.The pivot to perioperative settings is a multi-billion-dollar opportunity for maturing brands,aligning with the future of earlier cancer detection and the demand for cures.The strategic question is no longer if you shoul

6、d be here,but how you will win.This is not just a revenue extension.Its a long-term strategic play.While maximizing brand value is key,the real prize is strategic.Leading companies are using the perioperative space to secure a foothold in growing markets,establish PD-1/PD-L1 assets as the backbone f